» Articles » PMID: 24874920

Antagomirs Targeting MicroRNA-134 Increase Hippocampal Pyramidal Neuron Spine Volume in Vivo and Protect Against Pilocarpine-induced Status Epilepticus

Overview
Specialty Neurology
Date 2014 May 31
PMID 24874920
Citations 58
Authors
Affiliations
Soon will be listed here.
Abstract

Emerging data support roles for microRNA (miRNA) in the pathogenesis of various neurologic disorders including epilepsy. MicroRNA-134 (miR-134) is enriched in dendrites of hippocampal neurons, where it negatively regulates spine volume. Recent work identified upregulation of miR-134 in experimental and human epilepsy. Targeting miR-134 in vivo using antagomirs had potent anticonvulsant effects against kainic acid-induced seizures and was associated with a reduction in dendritic spine number. In the present study, we measured dendritic spine volume in mice injected with miR-134-targeting antagomirs and tested effects of the antagomirs on status epilepticus triggered by the cholinergic agonist pilocarpine. Morphometric analysis of over 6,400 dendritic spines in Lucifer yellow-injected CA3 pyramidal neurons revealed increased spine volume in mice given antagomirs compared to controls that received a scrambled sequence. Treatment of mice with miR-134 antagomirs did not alter performance in a behavioral test (novel object location). Status epilepticus induced by pilocarpine was associated with upregulation of miR-134 within the hippocampus of mice. Pretreatment of mice with miR-134 antagomirs reduced the proportion of animals that developed status epilepticus following pilocarpine and increased animal survival. In antagomir-treated mice that did develop status epilepticus, seizure onset was delayed and total seizure power was reduced. These studies provide in vivo evidence that miR-134 regulates spine volume in the hippocampus and validation of the seizure-suppressive effects of miR-134 antagomirs in a model with a different triggering mechanism, indicating broad conservation of anticonvulsant effects.

Citing Articles

Circulating miR-134 in mesial temporal lobe epilepsy: implications in hippocampal sclerosis development and drug resistance.

Guerra Leal B, Carvalho C, Santos C, Samoes R, Martins-Ferreira R, Teixeira C Front Mol Neurosci. 2025; 17:1512860.

PMID: 39744540 PMC: 11688299. DOI: 10.3389/fnmol.2024.1512860.


Small Differences and Big Changes: The Many Variables of MicroRNA Expression and Function in the Brain.

Parkins E, Gross C J Neurosci. 2024; 44(32).

PMID: 39111834 PMC: 11308354. DOI: 10.1523/JNEUROSCI.0365-24.2024.


Pathogenesis, diagnosis, and treatment of epilepsy: electromagnetic stimulation-mediated neuromodulation therapy and new technologies.

Jiao D, Xu L, Gu Z, Yan H, Shen D, Gu X Neural Regen Res. 2024; 20(4):917-935.

PMID: 38989927 PMC: 11438347. DOI: 10.4103/NRR.NRR-D-23-01444.


Fetal Brain-Derived Exosomal miRNAs from Maternal Blood: Potential Diagnostic Biomarkers for Fetal Alcohol Spectrum Disorders (FASDs).

Darbinian N, Hampe M, Martirosyan D, Bajwa A, Darbinyan A, Merabova N Int J Mol Sci. 2024; 25(11).

PMID: 38892014 PMC: 11172088. DOI: 10.3390/ijms25115826.


Tumor Suppressor MicroRNAs in Clinical and Preclinical Trials for Neurological Disorders.

Lui A, Do T, Alzayat O, Yu N, Phyu S, Santuya H Pharmaceuticals (Basel). 2024; 17(4).

PMID: 38675388 PMC: 11054060. DOI: 10.3390/ph17040426.